Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of molecular marker in preparing pancreatic cancer prognosis evaluation product

A technology of molecular markers and prognosis assessment, applied in the field of biomedicine, can solve the problems of low sensitivity, high sensitivity, and limited value of early diagnosis of pancreatic cancer, and achieve the effect of improving accuracy

Inactive Publication Date: 2017-05-31
北京致成生物医学科技有限公司
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CA19-9 alone is not accurate as an indicator for the diagnosis of pancreatic cancer, and its sensitivity is low, and it is also elevated in other gastrointestinal tumors and benign diseases, so its value for early diagnosis of pancreatic cancer is limited
In addition, some genetic tumor markers are also used in the early diagnosis of clinical pancreatic cancer, but the purpose of diagnosis has not been achieved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of molecular marker in preparing pancreatic cancer prognosis evaluation product
  • Application of molecular marker in preparing pancreatic cancer prognosis evaluation product
  • Application of molecular marker in preparing pancreatic cancer prognosis evaluation product

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Survival analysis of pancreatic cancer based on TCGA database information Screening related genes

[0047] 1. Screening of clinical information

[0048] The clinical information of pancreatic cancer patients in the TCGA database was retrieved. As of December 10, 2015, a total of 185 clinical cases of pancreatic cancer were recorded in the TCGA database. These data were screened, and a total of 160 patients were included in the study. Patients with a history of other malignant tumors, who had received radiotherapy or chemotherapy were excluded during screening, and patients included in the study were required to contain clinical information and mRNA data.

[0049] 2. Survival study sample statistics

[0050] The statistical results of the survival time of 160 patients with pancreatic cancer are shown in the following table:

[0051] Table 1 Survival time statistics of 160 patients with pancreatic cancer

[0052] Survival time t (years) The number ...

Embodiment 2

[0059] Embodiment 2RT-PCR detects the correlation between gene expression content and survival time

[0060] 1. Materials

[0061] From October 2010 to December 2015, 5 patients with pancreatic cancer who underwent surgical resection in Peking Union Medical College Hospital and were confirmed by pathological examination were collected. After surgical treatment, the patients were followed up, and the peripheral blood of the patients was collected every year to detect the expression level changes of HCG4P6 and TOP1P2 genes (the survival time of the first patient was > 6 years, the survival time of the second patient was 5 years, and the survival time of the third patient was 5 years). The survival time of the first patient was 5 years, the survival time of the fourth patient was 3 years, and the survival time of the fifth patient was 2 years).

[0062] 2. Method

[0063] 2.1 Total RNA extraction from tissue samples

[0064] Total RNA was extracted from the peripheral blood of...

Embodiment 3

[0096] Embodiment 3 kit preparation

[0097] This embodiment provides a kit for evaluating the therapeutic effect of pancreatic cancer, which includes

[0098] 1. RNA extraction reagents include TRizol, chloroform, isopropanol, 75% ethanol and enzyme-free water;

[0099] 2. Reverse transcription reagents include 5xPrimerScript Buffer, PrimeScript RT Enzyme Mix I, OligodT Primer, Random 6mers and RNase Free dH 2 O;

[0100] 3. Quantitative PCR reagents include primer sequences for specific amplification of HCG4P6 and / or TOP1P2 as shown in Table 2, specifically:

[0101] (1) The kit includes specific amplification of HCG4P6: SEQ ID NO.1 and SEQ ID NO.2;

[0102] (2) The kit includes specific amplification of TOP1P2: SEQ ID NO.3 and SEQ ID NO.4;

[0103] (3) The kit includes specific amplification of HCG4P6 and TOP1P2: SEQ ID NO.1 and 2; SEQ ID NO.3 and 4.

[0104] The primer pair for specifically amplifying the housekeeping gene (GAPDH) is shown in SEQ ID NO:5 and SEQ ID NO...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a molecular marker for detecting pancreatic cancer. The molecular marker is HCG4P6 and / or TOP1P2 gene. The invention further discloses application of the molecular marker in preparing a pancreatic cancer prognosis evaluation production. The invention further discloses a pancreatic cancer prognosis evaluation kit. The kit comprises a specific-amplification HCG4P and / or TOP1P2 primer sequence. By means of the molecular marker, diagnosis, treatment, monitoring and prognosis of the pancreatic cancer are processed, and the molecular marker has significance in prognosis and treatment of the pancreatic cancer.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of molecular markers in the preparation of pancreatic cancer prognosis assessment products. Background technique [0002] Pancreatic cancer is one of the most malignant tumors and ranks fourth in the death rate of malignant tumors in Western countries. About 2.5 million people die of pancreatic cancer every year in the world. The incidence of pancreatic cancer in my country has been increasing year by year, and has grown rapidly in the past 20 years. The treatment of pancreatic cancer is mainly a combination of surgery, chemotherapy and radiotherapy, and its five-year survival rate is less than 5%. Due to the deep anatomical location of the pancreas, clinically specific symptoms such as abdominal pain, weight loss, and jaundice are difficult to detect, and most patients have already developed cancer metastasis when they are diagnosed. Liver metastasis of pancreatic ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6886C12Q1/6851C12Q2600/118C12Q2531/113C12Q2563/107
Inventor 刘昊
Owner 北京致成生物医学科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com